Association of plasma β-amyloid level and cognitive reserve with subsequent cognitive decline

JAMA

Volumn 305, Issue 3, 2011, Pages 261-266

  Yaffe, Kristine ^a,b,c   Weston, Andrea ^a   Graff Radford, Neill R ^d   Satterfield, Suzanne ^f   Simonsick, Eleanor M ^g   Younkin, Steven G ^e   Younkin, Linda H ^e   Kuller, Lewis ^h   Ayonayon, Hilsa N ^b   Ding, Jingzhong ⁱ   Harris, Tamara B ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e MAYO GRADUATE SCHOOL   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g NATIONAL INSTITUTE ON AGING   (United States)

^h UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4;

AGED; ARTICLE; COGNITIVE DEFECT; COGNITIVE RESERVE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UNITED STATES;

EID: 78751519245     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1995     Document Type: Article

References (33)

1. Prince M, Jackson J. World Alzheimer Report. London, England: Alzheimer's Disease International; 2009.
2. Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma Aβ 42/Aβ 40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64(3):354-362. (Pubitemid 46425689)
3. Lewczuk P, Kornhuber J, Vanmechelen E, et al. Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing. Exp Neurol. 2010;223(2):366-370.
4. Pesaresi M, Lovati C, Bertora P, et al. Plasma levels of β-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2006;27(6):904-905. (Pubitemid 44287903)
5. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid β protein levels. Arch Neurol. 2003;60(7):958-964. (Pubitemid 36858355)
6. Hansson O, Zetterberg H, Vanmechelen E, et al. Evaluation of plasma Aβ(40) and Aβ(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging. 2010;31(3):357-367.
7. Lopez OL, Kuller LH,Mehta PD, et al. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology. 2008;70(19):1664-1671.
8. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25(34):7709- 7717.
9. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131(pt 3):665-680.
10. Rowe CC, Ng S, Ackermann U, et al. Imaging β-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718-1725.
11. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837-1844.
12. Kemppainen NM, Aalto S, Karrasch M, et al. Cognitive reserve hypothesis: Pittsburgh compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol. 2008;63(1):112-118.
13. Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010;67(3):353-364.
14. Scarmeas N, Stern Y. Cognitive reserve: implications for diagnosis and prevention of Alzheimer's disease. Curr Neurol Neurosci Rep. 2004;4(5):374-380. (Pubitemid 39359935)
15. Stern Y. What is cognitive reserve? theory and research application of the reserve concept. J Int Neuropsychol Soc. 2002;8(3):448-460. (Pubitemid 34296102)
16. Yaffe K, Barnes D, Lindquist K, et al; Health ABC Investigators. Endogenous sex hormone levels and risk of cognitive decline in an older biracial cohort. Neurobiol Aging. 2007;28(2):171-178.
17. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48(8):314-318.
18. Bennett DA, Wilson RS, Schneider JA, et al. Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology. 2003;60(12):1909-1915. (Pubitemid 36736005)
19. Davis TC, Long SW, Jackson RH, et al. Rapid estimate of adult literacy in medicine: a shortened screening instrument. Fam Med. 1993;25(6):391-395.
20. Mehta KM, Simonsick EM, Rooks R, et al. Black and white differences in cognitive function test scores: what explains the difference? J Am Geriatr Soc. 2004;52(12):2120-2127.
21. Davis TC, Michielutte R, Askov EN, Williams MV, Weiss BD. Practical assessment of adult literacy in health care. Health Educ Behav. 1998;25(5):613-624.
22. Rothman R, Malone R, Bryant B, Horlen C, DeWalt D, Pignone M. The relationship between literacy and glycemic control in a diabetes disease-management program. Diabetes Educ. 2004;30(2):263-273. (Pubitemid 38515536)
23. Yaffe K, Barnes D, Nevitt M, Lui L-Y, Covinsky K. A prospective study of physical activity and cognitive decline in elderly women: womenwho walk. Arch Intern Med. 2001;161(14):1703-1708. (Pubitemid 32679544)
24. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.
25. Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR. Serum creatinine levels correlate with plasma amyloid β protein. Alzheimer Dis Assoc Disord. 2002;16(3):187-190. (Pubitemid 35001095)
26. Lambert JC, Schraen-Maschke S, Richard F, et al. Association of plasma amyloid β with risk of dementia: the prospective Three-City Study. Neurology. 2009;73(11):847-853.
27. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MMB. Plasma Aβ(1-40) and Aβ(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5(8):655-660.
28. Innogenetics. New prospects for research into Alzheimer's disease with INNO-BIA plasma Aβ forms: a standardized research test for measuring the concentrations of β-amyloid isoforms in blood. http://www.innogenetics.be/ documenten/BIA-plasma-litreview.pdf. Accessed May 26, 2010.
29. Mayeux R, Tang M-X, Jacobs DM, et al. Plasma amyloid β-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol. 1999;46(3):412-416.
30. Gravina SA, Ho L, Eckman CB, et al. Amyloid β protein (Aβ) in Alzheimer's disease brain: biochemical and immunocytochemical analysis with antibodies specific for forms ending at Aβ 40 or Aβ 42(43). J Biol Chem. 1995;270(13):7013-7016.
31. Pike KE, Savage G, Villemagne VL, et al. β-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130(Pt 11):2837-2844.
32. Cosentino SA, Stern Y, Sokolov E, et al. Plasma β-amyloid and cognitive decline. Arch Neurol. 2010;67(12):1485-1490.
33. Kuller LH, Lopez OL, Newman A, et al. Risk factors for dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003;22(1):13-22. (Pubitemid 36131969)